VALUE OF PH-IMPEDANCE MONITORING PERFORMED ‘ON’ BID PROTON PUMP INHIBITOR THERAPY TO IDENTIFY NEED FOR ESCALATION OF REFLUX MANAGEMENT

Footnotes

No conflicts of interest exist and no writing assistance was obtained for this study.

Guarantor of the article: CPG. Author roles: CPG: study concept and design, data collection and analysis, manuscript preparation and critical review; RT, FZ, SR, ES: data collection and analysis, critical manuscript review; BDR: data analysis and manuscript preparation and critical review; MF, NdB, MV: data collection and critical manuscript review; DS: study concept and design, data collection and analysis, manuscript preparation and critical review

Disclosures: CPG: consultant for Medtronic, Diversatek, Ironwood, Isothrive, Takeda, and Quintiles RT; BDR, MF: no disclosures; NdB: speaker for Malesci; FZ: consultant/speaker for Takeda, Allergan, Biocodex, Vifor Pharma, Mayoli Spindler, Ipsen, Abbott, Reckitt Benckiser, Alfasigma; SR: consulting Medtronic, research support Diversatek Healthcare, Medtronic; ES: Lecture Fee: Medtronic, Takeda, Janssen, MSD, Abbvie, Malesci; Consulting: Medtronic, Takeda, Janssen, MSD, Reckitt Bencikser, Sofar, Unifarco, SILA, Oftagest; MFV: consultant for Medtronic, research support from Diversatek; DS: research grants: Reckitt Benckiser UK, Jinshan Technology China, Alfa Sigma Italy

Comments (0)

No login
gif